Symbio is currently owned by ARCHIMED, through MED Platform II, since 2023.

When did ARCHIMED acquire Symbio?

ARCHIMED acquired Symbio in 2023 (active for 3 years).

Home/Companies/Pharma/Symbio

Symbio

Pharma·

US·Active·3yr hold

Symbio is a TMT company, headquartered in France.

Entry

2023

Hold

3yr

Status

Active

Est. EV

–

Most recent investor

ARCHIMED

2 ownership periods

Key facts

HQFrance

SectorTMT

Symbio, based in NY, is a global full-service Clinical Research Organization (CRO) with offices in the US and Europe. In November 2023,…Read full notes

See the full ownership history.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Full fund context: vintage, strategy, region

4 portfolio peers in MED Platform II

3 comparable pharma deals from other GPs

Start free

Already a member? Sign in

Data refreshed weekly · Sourced from public filings